Retatrutide
Triple-receptor agonist (GIP/GLP-1/glucagon) at the research frontier.
Retatrutide
Background
Retatrutide (development code LY3437943) is an investigational single-molecule triple agonist targeting the GIP, GLP-1, and glucagon receptors. The addition of glucagon-receptor agonism to dual incretin activity is hypothesized to increase energy expenditure alongside appetite suppression, an approach studied in metabolic and obesity research.
Phase 2 trials reported dose-dependent reductions in body weight and HbA1c. As an investigational agent, retatrutide has not completed phase 3 development and is not approved for any use.
Selected literature
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526.
- Rosenstock J, et al. Retatrutide in patients with type 2 diabetes: a phase 2 trial. The Lancet. 2023;402(10401):529-544.
- Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist. Cell Metabolism. 2022;34(9):1234-1247.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
Retatrutide (LY3437943) is an investigational compound under development by Eli Lilly and Company with no approved or trademarked drug product. Catalyst Research Labs is not affiliated with Eli Lilly. Supplied as reference material only.
